Inhibiting hepatoblastoma growth in vitro and in vivo through blocking IGF2-AKT-mTOR-signaling

Ferdinand Wagner, Bente Henningsen, Melanie Eichenmüller, Beate Hagl, Jan Gödeke, Roland Kappler & Dietrich Von Schweinitz
Introduction: Hepatoblastoma is the most common malignant liver tumor in childhood. Since activation of IGF2-AKT-mTOR signaling plays a central role in the formation of embryonal tumors, blocking this pathway with rapamycin might be a new option for hepatoblastoma treatment. Materials and methods:[for full text, please go to the a.m. URL]